Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Monday, Barclays (LON:BARC) reiterated an Equalweight rating on Colgate-Palmolive Company (NYSE:CL) stock with a steady price target of $83.00. The consumer goods giant, currently valued at $70.8 billion, has seen its stock trading near its 52-week low of $82.68. According to InvestingPro data, analysts’ targets range from $83 to $116, with 5 analysts recently revising their earnings expectations downward for the upcoming period. Analysts highlighted Colgate’s significant sales in emerging markets, which account for roughly half of the company’s total sales of $20.1 billion. This market segment has allowed Colgate to benefit from inflationary pricing, contributing an average of 10.5% to emerging market growth over the past three years. This factor represents about 70% of Colgate’s total organic sales growth during that period. The company maintains impressive gross profit margins of 60.6%, as reported by InvestingPro, which shows the company’s pricing power and operational efficiency. InvestingPro subscribers can access detailed margin analysis and 10+ additional key insights about Colgate’s financial health.
However, as the impact of inflationary pricing begins to diminish and currency headwinds persist, Colgate faces reduced flexibility in its profit and loss statement to continue delivering what has been considered top-tier earnings growth and total shareholder return (TSR). Despite these challenges, the company has pointed to its ability to adjust other parts of its financials, such as selling, general and administrative expenses (SG&A) and items below the line, to sustain dollar-based earnings growth.
Barclays analysts noted their optimism that Colgate would maintain its advertising and promotion (A&P) spend to meet guidance. This approach would align with the strategy adopted since CEO Noel Wallace’s tenure, moving away from the previous tendency to cut A&P spending to achieve financial targets. In the fourth quarter, although organic sales and gross margins were weaker than anticipated, Colgate’s advertising expenditure still grew by 9% year-over-year.
The emphasis on preserving A&P spending is seen as a positive move for maintaining the brand’s market position and long-term growth, even as the company navigates a tighter margin for delivering on its financial guidance. Colgate’s performance in the emerging markets continues to be a critical factor in its overall financial health, and analysts are closely monitoring the company’s strategies to manage the evolving economic landscape.
In other recent news, Colgate-Palmolive has seen significant developments. The company reported fourth-quarter earnings per share of $0.91, slightly surpassing expectations, and generated $20.1 billion in revenue over the last twelve months. However, the company’s organic sales growth of 4.3% did not meet the anticipated 5.9% projection. Raymond (NSE:RYMD) James adjusted its price target for Colgate-Palmolive to $105, maintaining an Outperform rating, while Stifel and Deutsche Bank (ETR:DBKGn) revised their stock targets for the company to $95, maintaining a hold rating.
These adjustments come after a reported sales deceleration in Q4 that was more significant than expected. Colgate-Palmolive’s Hill’s pet nutrition brand saw a notable 25% growth in the fourth quarter of 2024, contributing significantly to the company’s overall growth. In response to anticipated foreign exchange headwinds and a slowdown in certain global markets, Colgate-Palmolive announced it would implement pricing adjustments in Latin America starting in the first quarter.
Despite these challenges, analysts from Raymond James, Stifel, and Deutsche Bank maintain confidence in the company’s strategic positioning and its potential for sustained growth. The company’s flexible operating structure, strong market shares, and increased household penetration are key factors that position the company for consistent sales and profit growth over time, according to the analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.